CN101632671A - 一种哌拉西林钠舒巴坦钠药物组合物混悬粉针剂及其新应用 - Google Patents
一种哌拉西林钠舒巴坦钠药物组合物混悬粉针剂及其新应用 Download PDFInfo
- Publication number
- CN101632671A CN101632671A CN200910018015A CN200910018015A CN101632671A CN 101632671 A CN101632671 A CN 101632671A CN 200910018015 A CN200910018015 A CN 200910018015A CN 200910018015 A CN200910018015 A CN 200910018015A CN 101632671 A CN101632671 A CN 101632671A
- Authority
- CN
- China
- Prior art keywords
- sodium
- piperacillin
- sulbactam sodium
- sulbactam
- powder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002347 injection Methods 0.000 title claims abstract description 60
- 239000007924 injection Substances 0.000 title claims abstract description 60
- 239000000843 powder Substances 0.000 title claims abstract description 58
- 239000000203 mixture Substances 0.000 title claims abstract description 20
- 239000003814 drug Substances 0.000 title claims abstract description 19
- WCMIIGXFCMNQDS-IDYPWDAWSA-M piperacillin sodium Chemical compound [Na+].O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC=CC=1)C(=O)N[C@@H]1C(=O)N2[C@@H](C([O-])=O)C(C)(C)S[C@@H]21 WCMIIGXFCMNQDS-IDYPWDAWSA-M 0.000 title claims abstract description 12
- 229960005264 piperacillin sodium Drugs 0.000 title claims abstract description 10
- 229960000614 sulbactam sodium Drugs 0.000 title claims description 85
- NKZMPZCWBSWAOX-IBTYICNHSA-M Sulbactam sodium Chemical compound [Na+].O=S1(=O)C(C)(C)[C@H](C([O-])=O)N2C(=O)C[C@H]21 NKZMPZCWBSWAOX-IBTYICNHSA-M 0.000 title claims description 45
- 210000000214 mouth Anatomy 0.000 claims abstract description 21
- 208000015181 infectious disease Diseases 0.000 claims abstract description 13
- 238000004108 freeze drying Methods 0.000 claims abstract description 12
- 238000004945 emulsification Methods 0.000 claims abstract description 9
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 56
- 239000000725 suspension Substances 0.000 claims description 48
- 238000002360 preparation method Methods 0.000 claims description 43
- 235000012000 cholesterol Nutrition 0.000 claims description 28
- 229960003964 deoxycholic acid Drugs 0.000 claims description 28
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 claims description 28
- 239000000839 emulsion Substances 0.000 claims description 23
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 23
- 229920000053 polysorbate 80 Polymers 0.000 claims description 23
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 21
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 20
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 15
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 15
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 15
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 15
- 239000008101 lactose Substances 0.000 claims description 15
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 11
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 10
- 229930195725 Mannitol Natural products 0.000 claims description 10
- 239000003795 chemical substances by application Substances 0.000 claims description 10
- 239000000594 mannitol Substances 0.000 claims description 10
- 235000010355 mannitol Nutrition 0.000 claims description 10
- 239000011780 sodium chloride Substances 0.000 claims description 10
- 239000008215 water for injection Substances 0.000 claims description 10
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 9
- 229930006000 Sucrose Natural products 0.000 claims description 9
- 239000008103 glucose Substances 0.000 claims description 9
- 239000005720 sucrose Substances 0.000 claims description 9
- 238000013019 agitation Methods 0.000 claims description 8
- 238000012856 packing Methods 0.000 claims description 8
- 238000001914 filtration Methods 0.000 claims description 7
- 238000010438 heat treatment Methods 0.000 claims description 7
- 239000007788 liquid Substances 0.000 claims description 7
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 6
- 239000012530 fluid Substances 0.000 claims description 6
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 4
- 206010006326 Breath odour Diseases 0.000 claims description 3
- 208000032139 Halitosis Diseases 0.000 claims description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 2
- 239000004471 Glycine Substances 0.000 claims description 2
- 239000000600 sorbitol Substances 0.000 claims description 2
- 238000005516 engineering process Methods 0.000 abstract description 13
- 229960005256 sulbactam Drugs 0.000 abstract description 6
- 229940090044 injection Drugs 0.000 description 42
- 238000012360 testing method Methods 0.000 description 12
- 239000000243 solution Substances 0.000 description 11
- 210000001519 tissue Anatomy 0.000 description 10
- 230000000052 comparative effect Effects 0.000 description 9
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 239000002245 particle Substances 0.000 description 7
- 230000003115 biocidal effect Effects 0.000 description 6
- 239000008187 granular material Substances 0.000 description 6
- 239000002502 liposome Substances 0.000 description 5
- 230000007774 longterm Effects 0.000 description 5
- 229920000136 polysorbate Polymers 0.000 description 5
- FKENQMMABCRJMK-RITPCOANSA-N sulbactam Chemical compound O=S1(=O)C(C)(C)[C@H](C(O)=O)N2C(=O)C[C@H]21 FKENQMMABCRJMK-RITPCOANSA-N 0.000 description 5
- 230000003203 everyday effect Effects 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 206010059866 Drug resistance Diseases 0.000 description 3
- 229930182555 Penicillin Natural products 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 150000002960 penicillins Chemical class 0.000 description 3
- 230000002980 postoperative effect Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 229930186147 Cephalosporin Natural products 0.000 description 2
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 2
- CTKXFMQHOOWWEB-UHFFFAOYSA-N Ethylene oxide/propylene oxide copolymer Chemical compound CCCOC(C)COCCO CTKXFMQHOOWWEB-UHFFFAOYSA-N 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- 206010052428 Wound Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 229940124587 cephalosporin Drugs 0.000 description 2
- 150000001780 cephalosporins Chemical class 0.000 description 2
- 239000002738 chelating agent Substances 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- YMTINGFKWWXKFG-UHFFFAOYSA-N fenofibrate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)C)=CC=C1C(=O)C1=CC=C(Cl)C=C1 YMTINGFKWWXKFG-UHFFFAOYSA-N 0.000 description 2
- 229960002297 fenofibrate Drugs 0.000 description 2
- 229940093181 glucose injection Drugs 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000000155 melt Substances 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 229960002292 piperacillin Drugs 0.000 description 2
- 229920001993 poloxamer 188 Polymers 0.000 description 2
- 229940044519 poloxamer 188 Drugs 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000012109 statistical procedure Methods 0.000 description 2
- 241000588624 Acinetobacter calcoaceticus Species 0.000 description 1
- 206010061623 Adverse drug reaction Diseases 0.000 description 1
- 206010066995 Alveolar osteitis Diseases 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 1
- 108090000204 Dipeptidase 1 Proteins 0.000 description 1
- 208000001695 Dry Socket Diseases 0.000 description 1
- 208000036649 Dysbacteriosis Diseases 0.000 description 1
- 208000027244 Dysbiosis Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 206010060891 General symptom Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 241000588656 Neisseriaceae Species 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- 208000009019 Pericoronitis Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 235000010401 Prunus avium Nutrition 0.000 description 1
- 241001290151 Prunus avium subsp. avium Species 0.000 description 1
- 208000028346 Pseudomonas aeruginosa infectious disease Diseases 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 201000002820 alveolar periostitis Diseases 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000000680 avirulence Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229910001423 beryllium ion Inorganic materials 0.000 description 1
- 239000003782 beta lactam antibiotic agent Substances 0.000 description 1
- 102000006635 beta-lactamase Human genes 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 229960004261 cefotaxime Drugs 0.000 description 1
- GPRBEKHLDVQUJE-VINNURBNSA-N cefotaxime Chemical compound N([C@@H]1C(N2C(=C(COC(C)=O)CS[C@@H]21)C(O)=O)=O)C(=O)/C(=N/OC)C1=CSC(N)=N1 GPRBEKHLDVQUJE-VINNURBNSA-N 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000007957 coemulsifier Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000007140 dysbiosis Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 229910000037 hydrogen sulfide Inorganic materials 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 238000005360 mashing Methods 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229960000282 metronidazole Drugs 0.000 description 1
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 239000006070 nanosuspension Substances 0.000 description 1
- 208000001297 phlebitis Diseases 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 208000003265 stomatitis Diseases 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000010731 swelling symptom Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000004357 third molar Anatomy 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 239000002132 β-lactam antibiotic Substances 0.000 description 1
- 229940124586 β-lactam antibiotics Drugs 0.000 description 1
- 150000003952 β-lactams Chemical class 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200910018015XA CN101632671B (zh) | 2009-08-18 | 2009-08-18 | 一种哌拉西林钠舒巴坦钠药物组合物混悬粉针剂及其新应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200910018015XA CN101632671B (zh) | 2009-08-18 | 2009-08-18 | 一种哌拉西林钠舒巴坦钠药物组合物混悬粉针剂及其新应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101632671A true CN101632671A (zh) | 2010-01-27 |
| CN101632671B CN101632671B (zh) | 2010-12-29 |
Family
ID=41592113
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN200910018015XA Expired - Fee Related CN101632671B (zh) | 2009-08-18 | 2009-08-18 | 一种哌拉西林钠舒巴坦钠药物组合物混悬粉针剂及其新应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101632671B (un) |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101890014A (zh) * | 2010-07-29 | 2010-11-24 | 胡建荣 | 一种哌拉西林钠舒巴坦钠药物组合物脂质体注射剂 |
| CN101983629A (zh) * | 2010-08-06 | 2011-03-09 | 胡建荣 | 一种哌拉西林钠舒巴坦钠药物组合物微球注射剂 |
| CN102940607A (zh) * | 2012-11-01 | 2013-02-27 | 哈药集团制药总厂 | 一种氨苄西林舒巴坦钠药物组合物注射剂及其制备方法 |
| CN102940636A (zh) * | 2012-11-01 | 2013-02-27 | 哈药集团制药总厂 | 一种哌拉西林舒巴坦钠药物组合物注射剂及其制备方法 |
| JP2015531778A (ja) * | 2012-09-14 | 2015-11-05 | ベイジン シンティエンユー テクノロジー ディベロップメント シーオー エルティーディー | ピペラシリンナトリウムとスルバクタムナトリウムの共晶及びその製造方法、並びに当該共晶を含む医薬組成物及びその応用 |
| CN105497032A (zh) * | 2016-01-10 | 2016-04-20 | 苏州二叶制药有限公司 | 一种注射用哌拉西林钠舒巴坦钠组合物 |
| CN105560243A (zh) * | 2016-01-10 | 2016-05-11 | 苏州二叶制药有限公司 | 一种注射用哌拉西林钠舒巴坦钠组合物的制备方法 |
| CN107625772A (zh) * | 2017-09-30 | 2018-01-26 | 苏州二叶制药有限公司 | 一种哌拉西林钠他唑巴坦钠化合物的药物组合物 |
| CN107638394A (zh) * | 2017-09-30 | 2018-01-30 | 苏州二叶制药有限公司 | 一种哌拉西林钠舒巴坦钠化合物的药物组合物 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101322702B (zh) * | 2008-08-01 | 2010-08-18 | 海南百那医药发展有限公司 | 哌拉西林钠舒巴坦钠药物组合物制剂 |
-
2009
- 2009-08-18 CN CN200910018015XA patent/CN101632671B/zh not_active Expired - Fee Related
Cited By (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101890014A (zh) * | 2010-07-29 | 2010-11-24 | 胡建荣 | 一种哌拉西林钠舒巴坦钠药物组合物脂质体注射剂 |
| CN101983629A (zh) * | 2010-08-06 | 2011-03-09 | 胡建荣 | 一种哌拉西林钠舒巴坦钠药物组合物微球注射剂 |
| JP2015531778A (ja) * | 2012-09-14 | 2015-11-05 | ベイジン シンティエンユー テクノロジー ディベロップメント シーオー エルティーディー | ピペラシリンナトリウムとスルバクタムナトリウムの共晶及びその製造方法、並びに当該共晶を含む医薬組成物及びその応用 |
| CN102940607A (zh) * | 2012-11-01 | 2013-02-27 | 哈药集团制药总厂 | 一种氨苄西林舒巴坦钠药物组合物注射剂及其制备方法 |
| CN102940636A (zh) * | 2012-11-01 | 2013-02-27 | 哈药集团制药总厂 | 一种哌拉西林舒巴坦钠药物组合物注射剂及其制备方法 |
| CN105497032A (zh) * | 2016-01-10 | 2016-04-20 | 苏州二叶制药有限公司 | 一种注射用哌拉西林钠舒巴坦钠组合物 |
| CN105560243A (zh) * | 2016-01-10 | 2016-05-11 | 苏州二叶制药有限公司 | 一种注射用哌拉西林钠舒巴坦钠组合物的制备方法 |
| CN105497032B (zh) * | 2016-01-10 | 2018-09-18 | 苏州二叶制药有限公司 | 一种注射用哌拉西林钠舒巴坦钠组合物 |
| CN105560243B (zh) * | 2016-01-10 | 2018-09-18 | 苏州二叶制药有限公司 | 一种注射用哌拉西林钠舒巴坦钠组合物的制备方法 |
| CN107625772A (zh) * | 2017-09-30 | 2018-01-26 | 苏州二叶制药有限公司 | 一种哌拉西林钠他唑巴坦钠化合物的药物组合物 |
| CN107638394A (zh) * | 2017-09-30 | 2018-01-30 | 苏州二叶制药有限公司 | 一种哌拉西林钠舒巴坦钠化合物的药物组合物 |
| CN107638394B (zh) * | 2017-09-30 | 2020-07-07 | 苏州二叶制药有限公司 | 一种哌拉西林钠舒巴坦钠化合物的药物组合物 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101632671B (zh) | 2010-12-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101632671B (zh) | 一种哌拉西林钠舒巴坦钠药物组合物混悬粉针剂及其新应用 | |
| US6063405A (en) | Sustained release delivery system | |
| US8323643B2 (en) | Methods for treating adhesive capsulitis | |
| CN101703506B (zh) | 一种美洛西林钠舒巴坦钠药物组合物混悬粉针剂及其新应用 | |
| MX2014004792A (es) | Metodo de tratamiento o reduccion de efp. | |
| CN101632677B (zh) | 一种头孢哌酮钠他唑巴坦钠药物组合物混悬粉针剂及其新应用 | |
| CN101632660A (zh) | 一种阿莫西林钠舒巴坦钠药物组合物混悬粉针剂及其新应用 | |
| CN101632670B (zh) | 一种哌拉西林钠他唑巴坦钠药物组合物混悬粉针剂及其新应用 | |
| KR101503111B1 (ko) | 혈장-적응성 완전 전해질 용액 | |
| CN106309473A (zh) | 包含高浓度生物发酵透明质酸钠的聚合物基质组合物及其用途 | |
| CN102342931B (zh) | 替莫唑胺的可注射的胃肠外用药物制剂及其制备方法 | |
| WO1997011681A1 (en) | Sustained release delivery system and long acting narcotic analgesics and antagonists | |
| CN100356921C (zh) | 一种硫酸头孢匹罗组合物及其制备方法 | |
| CN1245074A (zh) | 减弱阴道酸度的药剂和用途 | |
| EP3525769A1 (de) | Schmelztablette enthaltend burlulipase und daraus hergestellte pharmazeutische zusammensetzung | |
| CN101810610B (zh) | 一种阿莫西林钠氟氯西林钠药物组合物脂质体注射剂 | |
| WO2024160247A1 (zh) | 含β-内酰胺酶抑制剂的药物组合物及其应用 | |
| CN102188395B (zh) | 一种更稳定的美罗培南注射剂及其制备方法 | |
| CN101637456B (zh) | 一种头孢孟多酯钠混悬粉针剂及其新应用 | |
| CN101721371B (zh) | 一种盐酸头孢他美酯亚微乳固体制剂及其应用 | |
| CN101700234B (zh) | 一种氟氯西林钠混悬粉针剂及其应用 | |
| CN103142587A (zh) | 阿莫西林钠克拉维酸钾药物组合物及其制备方法 | |
| CN103127129A (zh) | 头孢呋辛钠药物组合物及其制备方法 | |
| CN102008461A (zh) | 一种注射用布洛芬药物组合物 | |
| CN102008455A (zh) | 一种用于治疗奶牛乳腺炎的冻干粉制剂 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C57 | Notification of unclear or unknown address | ||
| DD01 | Delivery of document by public notice |
Addressee: Wang Ming Document name: Notification of Passing Preliminary Examination of the Application for Invention |
|
| C06 | Publication | ||
| PB01 | Publication | ||
| C57 | Notification of unclear or unknown address | ||
| DD01 | Delivery of document by public notice |
Addressee: Wang Ming Document name: Notification that Application Deemed not to be Proposed |
|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| DD01 | Delivery of document by public notice |
Addressee: Wang Ming Document name: Notification of Publication and of Entering the Substantive Examination Stage of the Application for Invention |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20101229 Termination date: 20160818 |